These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 7873659)

  • 1. A facile, water-soluble method for modification of proteins with DOTA. Use of elevated temperature and optimized pH to achieve high specific activity and high chelate stability in radiolabeled immunoconjugates.
    Lewis MR; Raubitschek A; Shively JE
    Bioconjug Chem; 1994; 5(6):565-76. PubMed ID: 7873659
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Maleimidocysteineamido-DOTA derivatives: new reagents for radiometal chelate conjugation to antibody sulfhydryl groups undergo pH-dependent cleavage reactions.
    Lewis MR; Shively JE
    Bioconjug Chem; 1998; 9(1):72-86. PubMed ID: 9460549
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimized conditions for chelation of yttrium-90-DOTA immunoconjugates.
    Kukis DL; DeNardo SJ; DeNardo GL; O'Donnell RT; Meares CF
    J Nucl Med; 1998 Dec; 39(12):2105-10. PubMed ID: 9867151
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biodistribution of 111In- and 90Y-labeled DOTA and maleimidocysteineamido-DOTA conjugated to chimeric anticarcinoembryonic antigen antibody in xenograft-bearing nude mice: comparison of stable and chemically labile linker systems.
    Williams LE; Lewis MR; Bebb GG; Clarke KG; Odom-Maryon TL; Shively JE; Raubitschek AA
    Bioconjug Chem; 1998; 9(1):87-93. PubMed ID: 9460550
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 90Y-DOTA-hLL2: an agent for radioimmunotherapy of non-Hodgkin's lymphoma.
    Griffiths GL; Govindan SV; Sharkey RM; Fisher DR; Goldenberg DM
    J Nucl Med; 2003 Jan; 44(1):77-84. PubMed ID: 12515879
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Trifunctional conjugation reagents. Reagents that contain a biotin and a radiometal chelation moiety for application to extracorporeal affinity adsorption of radiolabeled antibodies.
    Wilbur DS; Chyan MK; Hamlin DK; Kegley BB; Nilsson R; Sandberg BE; Brechbiel M
    Bioconjug Chem; 2002; 13(5):1079-92. PubMed ID: 12236790
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An improved method for conjugating monoclonal antibodies with N-hydroxysulfosuccinimidyl DOTA.
    Lewis MR; Kao JY; Anderson AL; Shively JE; Raubitschek A
    Bioconjug Chem; 2001; 12(2):320-4. PubMed ID: 11312695
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preparation and radiolabeling of a lyophilized (kit) formulation of DOTA-rituximab with ⁹⁰Y and ¹¹¹In for domestic radioimmunotherapy and radioscintigraphy of non-Hodgkin's lymphoma.
    Gholipour N; Jalilian AR; Khalaj A; Johari-Daha F; Yavari K; Sabzevari O; Khanchi AR; Akhlaghi M
    Daru; 2014 Jul; 22(1):58. PubMed ID: 25074720
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Labeling monoclonal antibodies with 90yttrium- and 111indium-DOTA chelates: a simple and efficient method.
    Li M; Meares CF; Zhong GR; Miers L; Xiong CY; DeNardo SJ
    Bioconjug Chem; 1994; 5(2):101-4. PubMed ID: 8031871
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of (64)Cu-complexing bifunctional chelators for radioimmunoconjugation: labeling efficiency, specific activity, and in vitro/in vivo stability.
    Cooper MS; Ma MT; Sunassee K; Shaw KP; Williams JD; Paul RL; Donnelly PS; Blower PJ
    Bioconjug Chem; 2012 May; 23(5):1029-39. PubMed ID: 22471317
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mass spectral analyses of labile DOTA-NHS and heterogeneity determination of DOTA or DM1 conjugated anti-PSMA antibody for prostate cancer therapy.
    Lu SX; Takach EJ; Solomon M; Zhu Q; Law SJ; Hsieh FY
    J Pharm Sci; 2005 Apr; 94(4):788-97. PubMed ID: 15729708
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Labeling of monoclonal antibody conjugates with 90Y.
    Motta-Hennessy C; Sharkey RM; Goldenberg DM
    Int J Rad Appl Instrum A; 1991; 42(5):421-6. PubMed ID: 1646187
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of humoral immune responses against a macrocyclic chelating agent (DOTA) in cancer patients receiving radioimmunoconjugates for imaging and therapy.
    Kosmas C; Snook D; Gooden CS; Courtenay-Luck NS; McCall MJ; Meares CF; Epenetos AA
    Cancer Res; 1992 Feb; 52(4):904-11. PubMed ID: 1737353
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of DOTA and NODAGA as chelators for (64)Cu-labeled immunoconjugates.
    Ghosh SC; Pinkston KL; Robinson H; Harvey BR; Wilganowski N; Gore K; Sevick-Muraca EM; Azhdarinia A
    Nucl Med Biol; 2015 Feb; 42(2):177-83. PubMed ID: 25457653
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A comparative study of copper-67 radiolabeling and kinetic stabilities of antibody-macrocycle chelate conjugates.
    Kukis DL; Diril H; Greiner DP; DeNardo SJ; DeNardo GL; Salako QA; Meares CF
    Cancer; 1994 Feb; 73(3 Suppl):779-86. PubMed ID: 8306260
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis and evaluation of novel bifunctional chelating agents based on 1,4,7,10-tetraazacyclododecane-N,N',N",N"'-tetraacetic acid for radiolabeling proteins.
    Chappell LL; Ma D; Milenic DE; Garmestani K; Venditto V; Beitzel MP; Brechbiel MW
    Nucl Med Biol; 2003 Aug; 30(6):581-95. PubMed ID: 12900284
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Investigations of N-linked macrocycles for 111In and 90Y labeling of proteins.
    Wu C; Virzi F; Hnatowich DJ
    Int J Rad Appl Instrum B; 1992 Feb; 19(2):239-44. PubMed ID: 1601676
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Radiolabeling and biological evaluation of DOTA-Ph-Al derivative conjugated to anti-EGFR antibody ior egf/r3 for targeted tumor imaging and therapy.
    Pnwar P; Iznaga-Escobar N; Mishra P; Srivastava V; Sharma RK; Chandra R; Mishra AK
    Cancer Biol Ther; 2005 Aug; 4(8):854-60. PubMed ID: 16082184
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High-specific-activity 111In-labeled anticarcinoembryonic antigen monoclonal antibody: improved method for the synthesis of diethylenetriaminepentaacetic acid conjugates.
    Paxton RJ; Jakowatz JG; Beatty JD; Beatty BG; Vlahos WG; Williams LE; Clark BR; Shively JE
    Cancer Res; 1985 Nov; 45(11 Pt 2):5694-9. PubMed ID: 4053042
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prelabeling of chimeric monoclonal antibody L6 with 90yttrium- and 111indium-1,4,7,10-tetraazacyclododecane-N,N',N",N"'-tetraacetic acid (DOTA) chelates for radioimmunodiagnosis and therapy.
    Li M; Meares CF; Salako Q; Kukis DL; Zhong GR; Miers L; DeNardo SJ
    Cancer Res; 1995 Dec; 55(23 Suppl):5726s-5728s. PubMed ID: 7493335
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.